Stanford University
Showing 381-400 of 730 Results
-
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Amit Manhas
Instructor, Cardiovascular Institute
BioDr. Amit Manhas is an instructor at the Stanford Cardiovascular Institute, specializing in cardiovascular disease modeling, cardio-oncology, and stem cell biology. Dr. Manhas earned his PhD in Biological Sciences from the Pharmacology Division at the CSIR-Central Drug Research Institute in Lucknow, India, where his doctoral research focused on cardioprotective mechanisms in ischemic injury.
-
David J. Maron
C. F. Rehnborg Professor and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Maron is the Co-Chair and Principal Investigator of the ISCHEMIA trial, and Co-Chair of the ISCHEMIA-CKD trial. These large, international, NIH-funded studies will determine whether an initial invasive strategy of cardiac catheterization and revascularization plus optimal medical therapy will reduce cardiovascular events in patients with and without chronic kidney disease and at least moderate ischemia compared to an initial conservative strategy of optimal medical therapy alone.
-
Alison Marsden
Douglass M. and Nola Leishman Professor of Cardiovascular Diseases, Professor of Pediatrics (Cardiology) and of Bioengineering and, by courtesy, of Mechanical Engineering
Current Research and Scholarly InterestsThe Cardiovascular Biomechanics Computation Lab at Stanford develops novel computational methods for the study of cardiovascular disease progression, surgical methods, and medical devices. We have a particular interest in pediatric cardiology, and use virtual surgery to design novel surgical concepts for children born with heart defects.
-
AC Matin
Member, Cardiovascular Institute
Current Research and Scholarly Interests1. Improvement of our newly discovered cancer prodrug regimen that permits noninvaisve visualization of drug activation. 2. Tracking tumors & cancer metastases using bacterial magnetite and newly developed single-cell tracking by MRI. 3. Molecular basis of bacterial planktonic and biofilm antibiotic resistance on Earth and under space microgravity -- development of new countermeasures; 4. Bioremediation.
-
Michael V. McConnell, MD, MSEE
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Lettie McGuire, EdM
Web Developer 1, Genetics
BioHarvard Graduate School of Education
Neuroscience Informed Research Design -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy. She is a Senior Advisor at SandboxAQ and the Chair of the Investment Committee of the American Heart Association’s GRFW Venture Fund.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative and the Board of Directors at Danaher Corporation.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association and the American College of Cardiology.
